Cellectis S.A. ( CLLS) - Key Metrics
CLLS Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0.05 | -$0.22 | -$0.14 | -$0.14 |
| 2026Q1 | $0.06 | -$0.18 | -$0.15 | -$0.16 |
| 2025Q4 | $0.10 | -$0.26 | -$0.10 | -$0.11 |
| 2025Q3 | $0.35 | $0.01 | -$0.02 | -$0.03 |
| 2025Q2 | $0.17 | -$0.24 | -$0.10 | -$0.11 |
CLLS Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -3.41 |
| 2026Q1 | 0% | -4.40 |
| 2025Q4 | 0% | -4.48 |
| 2025Q3 | 0% | 120.76 |
| 2025Q2 | 0% | -1.59 |
CLLS
Price: $3.05
52 week price:
Earnings Per Share: -0.64 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: France
Volume: 1.9 million
Ebitda: -29.3 millionMarket Capitalization: 291.0 million